125 related articles for article (PubMed ID: 38048519)
1. Microcystic Serous Cystadenoma Masquerading as Pancreatic Neuroendocrine Tumor on 99m Tc-HYNIC-TOC SPECT/CT.
Cai W; Dong Y; Zhao T; Dong A; Zhao Q
Clin Nucl Med; 2024 Feb; 49(2):e87-e89. PubMed ID: 38048519
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of
Xu J; Li Y; Xu X; Zhang J; Zhang Y; Yu X; Huang D
Ann Nucl Med; 2018 Aug; 32(7):446-452. PubMed ID: 29926342
[TBL] [Abstract][Full Text] [Related]
3. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors.
Qiao Z; Zhang J; Jin X; Huo L; Zhu Z; Xing H; Li F
Clin Nucl Med; 2015 May; 40(5):397-400. PubMed ID: 25706799
[TBL] [Abstract][Full Text] [Related]
4. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
Cwikla JB; Mikolajczak R; Pawlak D; Buscombe JR; Nasierowska-Guttmejer A; Bator A; Maecke HR; Walecki J
J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
[TBL] [Abstract][Full Text] [Related]
5. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of
Chen H; Li Y; Gao X; Shen X
Clin Imaging; 2018; 52():365-369. PubMed ID: 30248495
[TBL] [Abstract][Full Text] [Related]
7. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC.
Artiko V; Sobic-Saranovic D; Pavlovic S; Petrovic M; Zuvela M; Antic A; Matic S; Odalovic S; Petrovic N; Milovanovic A; Obradovic V
J BUON; 2012; 17(3):537-42. PubMed ID: 23033296
[TBL] [Abstract][Full Text] [Related]
9. Increased Uptake in Microcystic Serous Cystadenoma Mimicking Pancreatic Neuroendocrine Tumor on 68 Ga-DOTATATE PET/MRI.
Gao J; Liu C; Zhou J; Lin X; Zhang Y
Clin Nucl Med; 2023 Nov; 48(11):987-988. PubMed ID: 37756486
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.
Gabriel M; Muehllechner P; Decristoforo C; von Guggenberg E; Kendler D; Prommegger R; Profanter C; Moncayo R; Virgolini I
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):237-44. PubMed ID: 16172569
[TBL] [Abstract][Full Text] [Related]
11. The many faces of pancreatic serous cystadenoma: Radiologic and pathologic correlation.
Chu LC; Singhi AD; Haroun RR; Hruban RH; Fishman EK
Diagn Interv Imaging; 2017 Mar; 98(3):191-202. PubMed ID: 27614585
[TBL] [Abstract][Full Text] [Related]
12. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
Li F; Chen LB; Jing HL; Du YR; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):563-6. PubMed ID: 14650159
[TBL] [Abstract][Full Text] [Related]
13. (99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors.
Dong C; Zhao H; Yang S; Shi J; Huang J; Cui L; Zhong L; Jin X; Li F; Liu Z; Jia B; Wang F
Mol Pharm; 2013 Aug; 10(8):2925-33. PubMed ID: 23768172
[TBL] [Abstract][Full Text] [Related]
14. Serous cystadenoma mimicking cystic pancreatic neuroendocrine tumor on
Passand GT; Marichez A; Debordeaux F; Pinaquy JB; Chiche L
Diagn Interv Imaging; 2022 Nov; 103(11):563-565. PubMed ID: 36280584
[No Abstract] [Full Text] [Related]
15. Studies on batch formulation of a freeze dried kit for the preparation of
Mukherjee A; Korde A; Shinto A; Sarma HD; Kamaleswaran K; Dash A
Appl Radiat Isot; 2019 Mar; 145():180-186. PubMed ID: 30639635
[TBL] [Abstract][Full Text] [Related]
16. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors.
Parisella MG; Chianelli M; D'Alessandria C; Todino V; Mikolajczak R; Papini E; Dierckx RA; Scopinaro F; Signore A
Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):90-8. PubMed ID: 21068709
[TBL] [Abstract][Full Text] [Related]
17. Assessment of a well-differentiated pancreatic neuroendocrine tumor with
Prado-Wohlwend S; Ballesta-Moratalla M; Torres-Espallardo I; Del Olmo-García MI; Sánchez-Vañó R; Bello-Arques P
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(4):259-260. PubMed ID: 34218892
[No Abstract] [Full Text] [Related]
18. Long-acting octreotide treatment has no impact on tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine tumors.
Li Y; Xu J; Xu X; Zhang J; Zhang Y
Nucl Med Commun; 2019 Oct; 40(10):1005-1010. PubMed ID: 31365494
[TBL] [Abstract][Full Text] [Related]
19. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
Korde A; Mallia M; Shinto A; Sarma HD; Samuel G; Banerjee S
Cancer Biother Radiopharm; 2014 Nov; 29(9):387-94. PubMed ID: 25379612
[TBL] [Abstract][Full Text] [Related]
20. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
